Skye Bioscience, Inc. Overview
Pro stress-test →Skye Bioscience is a clinical stage biopharmaceutical company focused on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1).
Strategic Profile
Pro stress-test →Nimacimab has the potential to address unmet needs in obesity left by GLP-1 and incretin pharmaceuticals. Skye's CB1 inhibitor is unique in being a monoclonal antibody that works outside the brain, avoiding neuropsychiatric side effects seen with earlier CB1 inhibitors. The company is conducting a Phase 2 clinical trial assessing nimacimab as a monotherapy and in combination with GLP-1 receptor agonist (Wegovy).
Competitive Landscape
Pro stress-test →Skye competes in the rapidly expanding obesity therapeutics market dominated by GLP-1 receptor agonists (Novo Nordisk, Eli Lilly). Differentiation comes from CB1 mechanism and monoclonal antibody format avoiding CNS effects. Other emerging CB1 programs and dual/triple receptor agonists represent growing competition.
Industry Context
Skye Bioscience, Inc. operates in Biopharmaceuticals - Obesity and Metabolic Diseases.
Key facts
Founded: 2011 · Headquarters: San Diego, California · Market cap: $25M